Data from the DeLLphi-304 trial “clearly support tarlatamab as a preferable therapy” for SCLC in the second-line setting, said Charles M. Rudin, MD, PhD.

Cambridge: AstraZeneca has announced that Datroway (datopotamab deruxtecan or Dato-DXd) has received accelerated approval ...

Australians with a high risk of developing lung cancer can be screened for the disease free of charge through Medicare.This is ...

In a significant showcase for investors, BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will announce major advancements to its industry-leading oncology ...

This article explores how cancer biomarkers improve early detection, guide treatments and predict outcomes to transform ...

Far from science fiction, AI is already embedded in hundreds of FDA-cleared tools and is projected to multiply the value of ...

On June 2, the firm reaffirmed its Buy rating and maintained a $44 price target, more than double the current $18.21 share ...

Cancer drugs used in more than 100 countries have failed quality tests. But what are these drugs and how are they used?

Of course being diagnosed with metastatic non-small cell lung cancer (NSCLC) feels overwhelming. Between juggling treatments, managing symptoms and side effects, and dealing with the anxiety of a ...

Bio-Thera Solutions has initiated dosing in the randomised Phase III trial of the antibody-drug conjugate (ADC), BAT8006, ...

USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc.

Georgia Gardiner, 28, mother to two-year-old Arlo, from Leeds in West Yorkshire, has been told she has two years to live ...